[1]
Enchev, R.I.; Schulman, B.A.; Peter, M. Protein neddylation: Beyond cullin-RING ligases. Nat. Rev. Mol. Cell Biol., 2015, 16(1), 30-44. [http://dx.doi.org/10.1038/nrm3919]. [PMID: 25531226].
[2]
Rabut, G.; Peter, M. Function and regulation of protein neddylation. ‘Protein modifications: beyond the usual suspects’ review series. EMBO Rep., 2008, 9(10), 969-976. [http://dx.doi.org/10.1038/embor.2008.183]. [PMID: 18802447].
[3]
Oved, S.; Mosesson, Y.; Zwang, Y.; Santonico, E.; Shtiegman, K.; Marmor, M.D.; Kochupurakkal, B.S.; Katz, M.; Lavi, S.; Cesareni, G.; Yarden, Y. Conjugation to Nedd8 instigates ubiquitylation and down-regulation of activated receptor tyrosine kinases. J. Biol. Chem., 2006, 281(31), 21640-21651. [http://dx.doi.org/10.1074/jbc.M513034200]. [PMID: 16735510].
[4]
Xu, J.; Li, L.; Yu, G.; Ying, W.; Gao, Q.; Zhang, W.; Li, X.; Ding, C.; Jiang, Y.; Wei, D.; Duan, S.; Lei, Q.; Li, P.; Shi, T.; Qian, X.; Qin, J.; Jia, L. The neddylation-cullin 2-RBX1 E3 ligase axis targets tumor suppressor RhoB for degradation in liver cancer. Mol. Cell. Proteomics, 2015, 14(3), 499-509. [http://dx.doi.org/10.1074/mcp.M114.045211]. [PMID: 25540389].
[5]
El Motiam, A.; Vidal, S.; de la Cruz-Herrera, C.F.; Da Silva-Alvarez, S.; Baz-Martinez, M.; Seoane, R.; Vidal, A.; Rodriguez, M.S.; Xirodimas, D.P.; Carvalho, A.S.; Beck, H.C.; Matthiesen, R.; Collado, M.; Rivas, C. Interplay between sumoylation and neddylation regulates rpl11 localization and function. FASEB J., 2018. [http://dx.doi.org/10.1096/fj.201800341RR].
[6]
Huang, G.; Kaufman, A.J.; Ramanathan, Y.; Singh, B. SCCRO (DCUN1D1) promotes nuclear translocation and assembly of the neddylation E3 complex. J. Biol. Chem., 2011, 286(12), 10297-10304. [http://dx.doi.org/10.1074/jbc.M110.203729]. [PMID: 21247897].
[7]
Loftus, S.J.; Liu, G.; Carr, S.M.; Munro, S.; La Thangue, N.B. NEDDylation regulates E2F-1-dependent transcription. EMBO Rep., 2012, 13(9), 811-818. [http://dx.doi.org/10.1038/embor.2012.113]. [PMID: 22836579].
[8]
Zou, J.; Ma, W.; Li, J.; Littlejohn, R.; Zhou, H.; Kim, I.M.; Fulton, D.J.R.; Chen, W.; Weintraub, N.L.; Zhou, J.; Su, H. Neddylation mediates ventricular chamber maturation through repression of Hippo signaling. Proc. Natl. Acad. Sci. USA, 2018, 115(17), E4101-E4110. [http://dx.doi.org/10.1073/pnas.1719309115]. [PMID: 29632206].
[9]
Harper, J.W. Neddylating the guardian; Mdm2 catalyzed conjugation of Nedd8 to p53. Cell, 2004, 118(1), 2-4. [http://dx.doi.org/10.1016/j.cell.2004.06.015]. [PMID: 15242638].
[10]
Ma, T.; Chen, Y.; Zhang, F.; Yang, C.Y.; Wang, S.; Yu, X. RNF111-dependent neddylation activates DNA damage-induced ubiquitination. Mol. Cell, 2013, 49(5), 897-907. [http://dx.doi.org/10.1016/j.molcel.2013.01.006]. [PMID: 23394999].
[11]
Wu, J.T.; Lin, H.C.; Hu, Y.C.; Chien, C.T. Neddylation and deneddylation regulate Cul1 and Cul3 protein accumulation. Nat. Cell Biol., 2005, 7(10), 1014-1020. [http://dx.doi.org/10.1038/ncb1301]. [PMID: 16127432].
[12]
Li, L.; Liu, B.; Dong, T.; Lee, H.W.; Yu, J.; Zheng, Y.; Gao, H.; Zhang, Y.; Chu, Y.; Liu, G.; Niu, W.; Zheng, S.; Jeong, L.S.; Jia, L. Neddylation pathway regulates the proliferation and survival of macrophages. Biochem. Biophys. Res. Commun., 2013, 432(3), 494-498. [http://dx.doi.org/10.1016/j.bbrc.2013.02.028]. [PMID: 23416079].
[13]
Yao, W.T.; Wu, J.F.; Yu, G.Y.; Wang, R.; Wang, K.; Li, L.H.; Chen, P.; Jiang, Y.N.; Cheng, H.; Lee, H.W.; Yu, J.; Qi, H.; Yu, X.J.; Wang, P.; Chu, Y.W.; Yang, M.; Hua, Z.C.; Ying, H.Q.; Hoffman, R.M.; Jeong, L.S.; Jia, L.J. Suppression of tumor angiogenesis by targeting the protein neddylation pathway. Cell Death Dis., 2014, 5e1059 [http://dx.doi.org/10.1038/cddis.2014.21]. [PMID: 24525735].
[14]
Kandala, S.; Kim, I.M.; Su, H. Neddylation and deneddylation in cardiac biology. Am. J. Cardiovasc. Dis., 2014, 4(4), 140-158. [PMID: 25628956].
[15]
Mathewson, N.; Toubai, T.; Kapeles, S.; Sun, Y.; Oravecz-Wilson, K.; Tamaki, H.; Wang, Y.; Hou, G.; Sun, Y.; Reddy, P. Neddylation plays an important role in the regulation of murine and human dendritic cell function. Blood, 2013, 122(12), 2062-2073. [http://dx.doi.org/10.1182/blood-2013-02-486373]. [PMID: 23863900].
[16]
Hrecka, K.; Gierszewska, M.; Srivastava, S.; Kozaczkiewicz, L.; Swanson, S.K.; Florens, L.; Washburn, M.P.; Skowronski, J. Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle. Proc. Natl. Acad. Sci. USA, 2007, 104(28), 11778-11783. [http://dx.doi.org/10.1073/pnas.0702102104]. [PMID: 17609381].
[17]
Zubiete-Franco, I.; Fernández-Tussy, P.; Barbier-Torres, L.; Simon, J.; Fernández-Ramos, D.; Lopitz-Otsoa, F.; Gutiérrez-de Juan, V.; de Davalillo, S.L.; Duce, A.M.; Iruzubieta, P.; Taibo, D.; Crespo, J.; Caballeria, J.; Villa, E.; Aurrekoetxea, I.; Aspichueta, P.; Varela-Rey, M.; Lu, S.C.; Mato, J.M.; Beraza, N.; Delgado, T.C.; Martínez-Chantar, M.L. Deregulated neddylation in liver fibrosis. Hepatology, 2017, 65(2), 694-709. [http://dx.doi.org/10.1002/hep.28933]. [PMID: 28035772].
[18]
Ehrentraut, S.F.; Colgan, S.P. Implications of protein post-translational modifications in IBD. Inflamm. Bowel Dis., 2012, 18(7), 1378-1388. [http://dx.doi.org/10.1002/ibd.22859]. [PMID: 22223542].
[19]
Nekorchuk, M.D.; Sharifi, H.J.; Furuya, A.K.; Jellinger, R.; de Noronha, C.M. HIV relies on neddylation for ubiquitin ligase-mediated functions. Retrovirology, 2013, 10, 138. [http://dx.doi.org/10.1186/1742-4690-10-138]. [PMID: 24245672].
[20]
Liu, N.; Zhang, J.; Yang, X.; Jiao, T.; Zhao, X.; Li, W.; Zhu, J.; Yang, P.; Jin, J.; Peng, J.; Li, Z.; Ye, X. Hdm2 promotes neddylation of hepatitis b virus hbx to enhance its stability and function. J. Virol., 2017, 91(16), 91. [http://dx.doi.org/10.1128/JVI.00340-17]. [PMID: 28592528].
[21]
Chen, Y.; Neve, R.L.; Liu, H. Neddylation dysfunction in Alzheimer’s disease. J. Cell. Mol. Med., 2012, 16(11), 2583-2591. [http://dx.doi.org/10.1111/j.1582-4934.2012.01604.x]. [PMID: 22805479].
[22]
Zhou, W.; Xu, J.; Li, H.; Xu, M.; Chen, Z.J.; Wei, W.; Pan, Z.; Sun, Y. Neddylation e2 ube2f promotes the survival of lung cancer cells by activating crl5 to degrade noxa via the k11 linkage. Clin. Cancer Res., 2017, 23(4), 1104-1116. [http://dx.doi.org/10.1158/1078-0432.CCR-16-1585]. [PMID: 27591266].
[23]
Fernández-Ramos, D.; Martínez-Chantar, M.L. NEDDylation in liver cancer: The regulation of the RNA binding protein Hu antigen R. Pancreatology, 2015, 15(4)(Suppl.), S49-S54. [http://dx.doi.org/10.1016/j.pan.2015.03.006]. [PMID: 25841271].
[24]
Gao, F.; Cheng, J.; Shi, T.; Yeh, E.T. Neddylation of a breast cancer-associated protein recruits a class III histone deacetylase that represses NFkappaB-dependent transcription. Nat. Cell Biol., 2006, 8(10), 1171-1177. [http://dx.doi.org/10.1038/ncb1483]. [PMID: 16998474].
[25]
Wang, X.; Li, L.; Liang, Y.; Li, C.; Zhao, H.; Ye, D.; Sun, M.; Jeong, L.S.; Feng, Y.; Fu, S.; Jia, L.; Guo, X. Targeting the neddylation pathway to suppress the growth of prostate cancer cells: Therapeutic implication for the men’s cancer. BioMed Res. Int., 2014, 2014974309 [http://dx.doi.org/10.1155/2014/974309]. [PMID: 25093192].
[26]
Li, L.; Wang, M.; Yu, G.; Chen, P.; Li, H.; Wei, D.; Zhu, J.; Xie, L.; Jia, H.; Shi, J.; Li, C.; Yao, W.; Wang, Y.; Gao, Q.; Jeong, L.S.; Lee, H.W.; Yu, J.; Hu, F.; Mei, J.; Wang, P.; Chu, Y.; Qi, H.; Yang, M.; Dong, Z.; Sun, Y.; Hoffman, R.M.; Jia, L. Overactivated neddylation pathway as a therapeutic target in lung cancer. J. Natl. Cancer Inst., 2014, 106(6)dju083 [http://dx.doi.org/10.1093/jnci/dju083]. [PMID: 24853380].
[27]
McMillin, D.W.; Jacobs, H.M.; Delmore, J.E.; Buon, L.; Hunter, Z.R.; Monrose, V.; Yu, J.; Smith, P.G.; Richardson, P.G.; Anderson, K.C.; Treon, S.P.; Kung, A.L.; Mitsiades, C.S. Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma. Mol. Cancer Ther., 2012, 11(4), 942-951. [http://dx.doi.org/10.1158/1535-7163.MCT-11-0563]. [PMID: 22246439].
[28]
Yu, J.; Huang, W.L.; Xu, Q.G.; Zhang, L.; Sun, S.H.; Zhou, W.P.; Yang, F. Overactivated neddylation pathway in human hepatocellular carcinoma. Cancer Med., 2018. Epub ahead of print [http://dx.doi.org/10.1002/cam4.1578]. [PMID: 29846044].
[29]
Mansouri, S.; Zadeh, G. Neddylation in glioblastomas. Neuro-oncol., 2015, 17(10), 1305-1306. [http://dx.doi.org/10.1093/neuonc/nov165]. [PMID: 26395059].
[30]
Guihard, S.; Ramolu, L.; Macabre, C.; Wasylyk, B.; Noël, G.; Abecassis, J.; Jung, A.C. The NEDD8 conjugation pathway regulates p53 transcriptional activity and head and neck cancer cell sensitivity to ionizing radiation. Int. J. Oncol., 2012, 41(4), 1531-1540. [http://dx.doi.org/10.3892/ijo.2012.1584]. [PMID: 22895816].
[31]
Yang, J.; Hamid, O.; Carvajal, R.D. The need for neddylation: A key to achieving ned in uveal melanoma. Clin. Cancer Res., 2018, 24(15), 3477-3479. [http://dx.doi.org/10.1158/1078-0432.CCR-18-0020]. [PMID: 29610291].
[32]
Pan, W.W.; Zhou, J.J.; Yu, C.; Xu, Y.; Guo, L.J.; Zhang, H.Y.; Zhou, D.; Song, F.Z.; Fan, H.Y. Ubiquitin E3 ligase CRL4(CDT2/ DCAF2) as a potential chemotherapeutic target for ovarian surface epithelial cancer. J. Biol. Chem., 2013, 288(41), 29680-29691. [http://dx.doi.org/10.1074/jbc.M113.495069]. [PMID: 23995842].
[33]
McLarnon, A. Cancer: Mdm2-regulated stabilization of HuR by neddylation in HCC and colon cancer--a possible target for therapy. Nat. Rev. Gastroenterol. Hepatol., 2011, 9(1), 4. [PMID: 22158377].
[34]
Zhou, L.; Zhang, W.; Sun, Y.; Jia, L. Protein neddylation and its alterations in human cancers for targeted therapy. Cell. Signal., 2018, 44, 92-102. [http://dx.doi.org/10.1016/j.cellsig.2018.01.009]. [PMID: 29331584].
[35]
Jiang, Y.; Jia, L. Neddylation pathway as a novel anti-cancer target: Mechanistic investigation and therapeutic implication. Anticancer. Agents Med. Chem., 2015, 15(9), 1127-1133. [http://dx.doi.org/10.2174/1871520615666150305111257]. [PMID: 25742093].
[36]
Mo, Z.; Zhang, Q.; Liu, Z.; Lauer, J.; Shi, Y.; Sun, L.; Griffin, P.R.; Yang, X.L. Neddylation requires glycyl-tRNA synthetase to protect activated E2. Nat. Struct. Mol. Biol., 2016, 23(8), 730-737. [http://dx.doi.org/10.1038/nsmb.3250]. [PMID: 27348078].
[37]
Huang, D.T.; Ayrault, O.; Hunt, H.W.; Taherbhoy, A.M.; Duda, D.M.; Scott, D.C.; Borg, L.A.; Neale, G.; Murray, P.J.; Roussel, M.F.; Schulman, B.A. E2-RING expansion of the NEDD8 cascade confers specificity to cullin modification. Mol. Cell, 2009, 33(4), 483-495. [http://dx.doi.org/10.1016/j.molcel.2009.01.011]. [PMID: 19250909].
[38]
Xirodimas, D.P.; Saville, M.K.; Bourdon, J.C.; Hay, R.T.; Lane, D.P. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell, 2004, 118(1), 83-97. [http://dx.doi.org/10.1016/j.cell.2004.06.016]. [PMID: 15242646].
[39]
Zuo, W.; Huang, F.; Chiang, Y.J.; Li, M.; Du, J.; Ding, Y.; Zhang, T.; Lee, H.W.; Jeong, L.S.; Chen, Y.; Deng, H.; Feng, X.H.; Luo, S.; Gao, C.; Chen, Y.G. c-Cbl-mediated neddylation antagonizes ubiquitination and degradation of the TGF-β type II receptor. Mol. Cell, 2013, 49(3), 499-510. [http://dx.doi.org/10.1016/j.molcel.2012.12.002]. [PMID: 23290524].
[40]
Broemer, M.; Tenev, T.; Rigbolt, K.T.; Hempel, S.; Blagoev, B.; Silke, J.; Ditzel, M.; Meier, P. Systematic in vivo RNAi analysis identifies IAPs as NEDD8-E3 ligases. Mol. Cell, 2010, 40(5), 810-822. [http://dx.doi.org/10.1016/j.molcel.2010.11.011]. [PMID: 21145488].
[41]
He, S.; Cao, Y.; Xie, P.; Dong, G.; Zhang, L. The nedd8 non-covalent binding region in the smurf hect domain is critical to its ubiquitn ligase function. Sci. Rep., 2017, 7, 41364. [http://dx.doi.org/10.1038/srep41364]. [PMID: 28169289].
[42]
Noguchi, K.; Okumura, F.; Takahashi, N.; Kataoka, A.; Kamiyama, T.; Todo, S.; Hatakeyama, S. TRIM40 promotes neddylation of IKKγ and is downregulated in gastrointestinal cancers. Carcinogenesis, 2011, 32(7), 995-1004. [http://dx.doi.org/10.1093/carcin/bgr068]. [PMID: 21474709].
[43]
Rabut, G.; Le Dez, G.; Verma, R.; Makhnevych, T.; Knebel, A.; Kurz, T.; Boone, C.; Deshaies, R.J.; Peter, M. The TFIIH subunit Tfb3 regulates cullin neddylation. Mol. Cell, 2011, 43(3), 488-495. [http://dx.doi.org/10.1016/j.molcel.2011.05.032]. [PMID: 21816351].
[44]
Kurz, T.; Chou, Y.C.; Willems, A.R.; Meyer-Schaller, N.; Hecht, M.L.; Tyers, M.; Peter, M.; Sicheri, F. Dcn1 functions as a scaffold-type E3 ligase for cullin neddylation. Mol. Cell, 2008, 29(1), 23-35. [http://dx.doi.org/10.1016/j.molcel.2007.12.012]. [PMID: 18206966].
[45]
Kamitani, T.; Kito, K.; Fukuda-Kamitani, T.; Yeh, E.T. Targeting of NEDD8 and its conjugates for proteasomal degradation by NUB1. J. Biol. Chem., 2001, 276(49), 46655-46660. [http://dx.doi.org/10.1074/jbc.M108636200]. [PMID: 11585840].
[46]
Shamay, M.; Greenway, M.; Liao, G.; Ambinder, R.F.; Hayward, S.D. De novo DNA methyltransferase DNMT3b interacts with NEDD8-modified proteins. J. Biol. Chem., 2010, 285(47), 36377-36386. [http://dx.doi.org/10.1074/jbc.M110.155721]. [PMID: 20847044].
[47]
Cope, G.A.; Suh, G.S.; Aravind, L.; Schwarz, S.E.; Zipursky, S.L.; Koonin, E.V.; Deshaies, R.J. Role of predicted metalloprotease motif of Jab1/Csn5 in cleavage of Nedd8 from Cul1. Science, 2002, 298(5593), 608-611. [http://dx.doi.org/10.1126/science.1075901]. [PMID: 12183637].
[48]
Gan-Erdene, T.; Nagamalleswari, K.; Yin, L.; Wu, K.; Pan, Z.Q.; Wilkinson, K.D. Identification and characterization of DEN1, a deneddylase of the ULP family. J. Biol. Chem., 2003, 278(31), 28892-28900. [http://dx.doi.org/10.1074/jbc.M302890200]. [PMID: 12759362].
[49]
Brownell, J.E.; Sintchak, M.D.; Gavin, J.M.; Liao, H.; Bruzzese, F.J.; Bump, N.J.; Soucy, T.A.; Milhollen, M.A.; Yang, X.; Burkhardt, A.L.; Ma, J.; Loke, H.K.; Lingaraj, T.; Wu, D.; Hamman, K.B.; Spelman, J.J.; Cullis, C.A.; Langston, S.P.; Vyskocil, S.; Sells, T.B.; Mallender, W.D.; Visiers, I.; Li, P.; Claiborne, C.F.; Rolfe, M.; Bolen, J.B.; Dick, L.R. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol. Cell, 2010, 37(1), 102-111. [http://dx.doi.org/10.1016/j.molcel.2009.12.024]. [PMID: 20129059].
[50]
Soucy, T.A.; Smith, P.G.; Milhollen, M.A.; Berger, A.J.; Gavin, J.M.; Adhikari, S.; Brownell, J.E.; Burke, K.E.; Cardin, D.P.; Critchley, S.; Cullis, C.A.; Doucette, A.; Garnsey, J.J.; Gaulin, J.L.; Gershman, R.E.; Lublinsky, A.R.; McDonald, A.; Mizutani, H.; Narayanan, U.; Olhava, E.J.; Peluso, S.; Rezaei, M.; Sintchak, M.D.; Talreja, T.; Thomas, M.P.; Traore, T.; Vyskocil, S.; Weatherhead, G.S.; Yu, J.; Zhang, J.; Dick, L.R.; Claiborne, C.F.; Rolfe, M.; Bolen, J.B.; Langston, S.P. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature, 2009, 458(7239), 732-736. [http://dx.doi.org/10.1038/nature07884]. [PMID: 19360080].
[51]
Lukkarila, J.L.; da Silva, S.R.; Ali, M.; Shahani, V.M.; Xu, G.W.; Berman, J.; Roughton, A.; Dhe-Paganon, S.; Schimmer, A.D.; Gunning, P.T. Identification of nae inhibitors exhibiting potent activity in leukemia cells: Exploring the structural determinants of nae specificity. ACS Med. Chem. Lett., 2011, 2(8), 577-582. [http://dx.doi.org/10.1021/ml2000615]. [PMID: 24900352].
[52]
Lin, J.J.; Milhollen, M.A.; Smith, P.G.; Narayanan, U.; Dutta, A. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res., 2010, 70(24), 10310-10320. [http://dx.doi.org/10.1158/0008-5472.CAN-10-2062]. [PMID: 21159650].
[53]
Wang, Y.; Luo, Z.; Pan, Y.; Wang, W.; Zhou, X.; Jeong, L.S.; Chu, Y.; Liu, J.; Jia, L. Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells. Cancer Biol. Ther., 2015, 16(3), 420-429. [http://dx.doi.org/10.1080/15384047.2014.1003003]. [PMID: 25782162].
[54]
Luo, Z.; Yu, G.; Lee, H.W.; Li, L.; Wang, L.; Yang, D.; Pan, Y.; Ding, C.; Qian, J.; Wu, L.; Chu, Y.; Yi, J.; Wang, X.; Sun, Y.; Jeong, L.S.; Liu, J.; Jia, L. The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. Cancer Res., 2012, 72(13), 3360-3371. [http://dx.doi.org/10.1158/0008-5472.CAN-12-0388]. [PMID: 22562464].
[55]
Chen, P.; Hu, T.; Liang, Y.; Li, P.; Chen, X.; Zhang, J.; Ma, Y.; Hao, Q.; Wang, J.; Zhang, P.; Zhang, Y.; Zhao, H.; Yang, S.; Yu, J.; Jeong, L.S.; Qi, H.; Yang, M.; Hoffman, R.M.; Dong, Z.; Jia, L. Neddylation inhibition activates the extrinsic apoptosis pathway through atf4-chop-dr5 axis in human esophageal cancer cells. Clin. Cancer Res., 2016, 22(16), 4145-4157. [http://dx.doi.org/10.1158/1078-0432.CCR-15-2254]. [PMID: 26983464].
[56]
Jia, L.; Li, H.; Sun, Y. Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression. Neoplasia, 2011, 13(6), 561-569. [http://dx.doi.org/10.1593/neo.11420]. [PMID: 21677879].
[57]
Luo, Z.; Pan, Y.; Jeong, L.S.; Liu, J.; Jia, L. Inactivation of the Cullin (CUL)-RING E3 ligase by the NEDD8-activating enzyme inhibitor MLN4924 triggers protective autophagy in cancer cells. Autophagy, 2012, 8(11), 1677-1679. [http://dx.doi.org/10.4161/auto.21484]. [PMID: 22874562].
[58]
Paiva, C.; Godbersen, J.C.; Berger, A.; Brown, J.R.; Danilov, A.V. Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents. Cell Death Dis., 2015, 6, 1807. [http://dx.doi.org/10.1038/cddis.2015.161]. [PMID: 26158513].
[59]
Nawrocki, S.T.; Kelly, K.R.; Smith, P.G.; Keaton, M.; Carraway, H.; Sekeres, M.A.; Maciejewski, J.P.; Carew, J.S. The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine. Clin. Cancer Res., 2015, 21(2), 439-447. [http://dx.doi.org/10.1158/1078-0432.CCR-14-1960]. [PMID: 25388161].
[60]
Jazaeri, A.A.; Shibata, E.; Park, J.; Bryant, J.L.; Conaway, M.R.; Modesitt, S.C.; Smith, P.G.; Milhollen, M.A.; Berger, A.J.; Dutta, A. Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924. Mol. Cancer Ther., 2013, 12(10), 1958-1967. [http://dx.doi.org/10.1158/1535-7163.MCT-12-1028]. [PMID: 23939375].
[61]
Vanderdys, V.; Allak, A.; Guessous, F.; Benamar, M.; Read, P.W.; Jameson, M.J.; Abbas, T. The neddylation inhibitor pevonedistat (mln4924) suppresses and radiosensitizes head and neck squamous carcinoma cells and tumors. Mol. Cancer Ther., 2018, 17(2), 368-380. [http://dx.doi.org/10.1158/1535-7163.MCT-17-0083]. [PMID: 28838998].
[62]
Wei, D.; Li, H.; Yu, J.; Sebolt, J.T.; Zhao, L.; Lawrence, T.S.; Smith, P.G.; Morgan, M.A.; Sun, Y. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Cancer Res., 2012, 72(1), 282-293. [http://dx.doi.org/10.1158/0008-5472.CAN-11-2866]. [PMID: 22072567].
[63]
Jin, Y.; Zhang, P.; Wang, Y.; Jin, B.; Zhou, J.; Zhang, J.; Pan, J. Neddylation blockade diminishes hepatic metastasis by dampening cancer stem-like cells and angiogenesis in uveal melanoma. Clin. Cancer Res., 2018, 24(15), 3741-3754. [http://dx.doi.org/10.1158/1078-0432.CCR-17-1703]. [PMID: 29233905].
[64]
Kuo, K.L.; Ho, I.L.; Shi, C.S.; Wu, J.T.; Lin, W.C.; Tsai, Y.C.; Chang, H.C.; Chou, C.T.; Hsu, C.H.; Hsieh, J.T.; Chang, S.C.; Pu, Y.S.; Huang, K.H. MLN4924, a novel protein neddylation inhibitor, suppresses proliferation and migration of human urothelial carcinoma: In vitro and in vivo studies. Cancer Lett., 2015, 363(2), 127-136. [http://dx.doi.org/10.1016/j.canlet.2015.01.015]. [PMID: 25615422].
[65]
Hua, W.; Li, C.; Yang, Z.; Li, L.; Jiang, Y.; Yu, G.; Zhu, W.; Liu, Z.; Duan, S.; Chu, Y.; Yang, M.; Zhang, Y.; Mao, Y.; Jia, L. Suppression of glioblastoma by targeting the overactivated protein neddylation pathway. Neuro-oncol., 2015, 17(10), 1333-1343. [http://dx.doi.org/10.1093/neuonc/nov066]. [PMID: 25904638].
[66]
Shah, J.J.; Jakubowiak, A.J.; O’Connor, O.A.; Orlowski, R.Z.; Harvey, R.D.; Smith, M.R.; Lebovic, D.; Diefenbach, C.; Kelly, K.; Hua, Z.; Berger, A.J.; Mulligan, G.; Faessel, H.M.; Tirrell, S.; Dezube, B.J.; Lonial, S. Phase i study of the novel investigational nedd8-activating enzyme inhibitor pevonedistat (mln4924) in patients with relapsed/refractory multiple myeloma or lymphoma. Clin. Cancer Res., 2016, 22(1), 34-43. [http://dx.doi.org/10.1158/1078-0432.CCR-15-1237]. [PMID: 26561559].
[67]
Swords, R.T.; Erba, H.P.; DeAngelo, D.J.; Bixby, D.L.; Altman, J.K.; Maris, M.; Hua, Z.; Blakemore, S.J.; Faessel, H.; Sedarati, F.; Dezube, B.J.; Giles, F.J.; Medeiros, B.C. Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. Br. J. Haematol., 2015, 169(4), 534-543. [http://dx.doi.org/10.1111/bjh.13323]. [PMID: 25733005].
[68]
Swords, R.T.; Watts, J.; Erba, H.P.; Altman, J.K.; Maris, M.; Anwer, F.; Hua, Z.; Stein, H.; Faessel, H.; Sedarati, F.; Dezube, B.J.; Giles, F.J.; Medeiros, B.C.; DeAngelo, D.J. Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. Blood Cancer J., 2017, 7(2)e520 [http://dx.doi.org/10.1038/bcj.2017.1]. [PMID: 28157218].
[69]
Lockhart, A.C.; Bauer, T.M.; Aggarwal, C.; Lee, C.B.; Harvey, R.D.; Cohen, R.B.; Sedarati, F.; Nip, T.K.; Faessel, H.; Dash, A.B.; Dezube, B.J.; Faller, D.V.; Dowlati, A. Phase ib study of pevonedistat, a nedd8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. Invest. New Drugs, 2018, 37(1), 87-97. [http://dx.doi.org/10.1007/s10637-018-0610-0]. [PMID: 29781056].
[70]
Sarantopoulos, J.; Shapiro, G.I.; Cohen, R.B.; Clark, J.W.; Kauh, J.S.; Weiss, G.J.; Cleary, J.M.; Mahalingam, D.; Pickard, M.D.; Faessel, H.M.; Berger, A.J.; Burke, K.; Mulligan, G.; Dezube, B.J.; Harvey, R.D. Phase i study of the investigational nedd8-activating enzyme inhibitor pevonedistat (tak-924/mln4924) in patients with advanced solid tumors. Clin. Cancer Res., 2016, 22(4), 847-857. [http://dx.doi.org/10.1158/1078-0432.CCR-15-1338]. [PMID: 26423795].
[71]
Bhatia, S.; Pavlick, A.C.; Boasberg, P.; Thompson, J.A.; Mulligan, G.; Pickard, M.D.; Faessel, H.; Dezube, B.J.; Hamid, O. A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma. Invest. New Drugs, 2016, 34(4), 439-449. [http://dx.doi.org/10.1007/s10637-016-0348-5]. [PMID: 27056178].
[74]
An, H.; Statsyuk, A.V. An inhibitor of ubiquitin conjugation and aggresome formation. Chem. Sci. (Camb.), 2015, 6(9), 5235-5245. [http://dx.doi.org/10.1039/C5SC01351H]. [PMID: 28717502].
[75]
Mizutani, T.; Yoshimura, C.; Kondo, H.; Kitade, M.; Ohkubo, S. Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical
composition containing same, especially agent for prevention
and.or treatment of tumors etc based on NAE inhibitory effect.
EP3103802 2016.
[76]
Leung, C.H.; Chan, D.S.; Yang, H.; Abagyan, R.; Lee, S.M.; Zhu, G.Y.; Fong, W.F.; Ma, D.L. A natural product-like inhibitor of NEDD8-activating enzyme. Chem. Commun. (Camb.), 2011, 47(9), 2511-2513. [http://dx.doi.org/10.1039/c0cc04927a]. [PMID: 21240405].
[77]
Zhong, H.J.; Ma, V.P.; Cheng, Z.; Chan, D.S.; He, H.Z.; Leung, K.H.; Ma, D.L.; Leung, C.H. Discovery of a natural product inhibitor targeting protein neddylation by structure-based virtual screening. Biochimie, 2012, 94(11), 2457-2460. [http://dx.doi.org/10.1016/j.biochi.2012.06.004]. [PMID: 22709868].
[78]
Zhong, H.J.; Yang, H.; Chan, D.S.; Leung, C.H.; Wang, H.M.; Ma, D.L. A metal-based inhibitor of NEDD8-activating enzyme. PLoS One, 2012, 7(11)e49574 [http://dx.doi.org/10.1371/journal.pone.0049574]. [PMID: 23185368].
[79]
Zhong, H.J.; Wang, W.; Kang, T.S.; Yan, H.; Yang, Y.; Xu, L.; Wang, Y.; Ma, D.L.; Leung, C.H. A rhodium(iii) complex as an inhibitor of neural precursor cell expressed, developmentally down-regulated 8-activating enzyme with in vivo activity against inflammatory bowel disease. J. Med. Chem., 2017, 60(1), 497-503. [http://dx.doi.org/10.1021/acs.jmedchem.6b00250]. [PMID: 27976900].
[80]
Lu, P.; Liu, X.; Yuan, X.; He, M.; Wang, Y.; Zhang, Q.; Ouyang, P.K. Discovery of a novel nedd8 activating enzyme inhibitor with piperidin-4-amine scaffold by structure-based virtual screening. ACS Chem. Biol., 2016, 11(7), 1901-1907. [http://dx.doi.org/10.1021/acschembio.6b00159]. [PMID: 27135934].
[81]
Lu, P.; Guo, Y.; Zhu, L.; Xia, Y.; Zhong, Y.; Wang, Y. A novel NAE/UAE dual inhibitor LP0040 blocks neddylation and ubiquitination leading to growth inhibition and apoptosis of cancer cells. Eur. J. Med. Chem., 2018, 154, 294-304. [http://dx.doi.org/10.1016/j.ejmech.2018.05.027]. [PMID: 29843100].
[82]
Zhang, S.; Tan, J.; Lai, Z.; Li, Y.; Pang, J.; Xiao, J.; Huang, Z.; Zhang, Y.; Ji, H.; Lai, Y. Effective virtual screening strategy toward covalent ligands: identification of novel NEDD8-activating enzyme inhibitors. J. Chem. Inf. Model., 2014, 54(6), 1785-1797. [http://dx.doi.org/10.1021/ci5002058]. [PMID: 24857708].
[83]
Ma, H.; Zhuang, C.; Xu, X.; Li, J.; Wang, J.; Min, X.; Zhang, W.; Zhang, H.; Miao, Z. Discovery of benzothiazole derivatives as novel non-sulfamide NEDD8 activating enzyme inhibitors by target-based virtual screening. Eur. J. Med. Chem., 2017, 133, 174-183. [http://dx.doi.org/10.1016/j.ejmech.2017.03.076]. [PMID: 28388520].
[84]
Zhong, H.J.; Liu, L.J.; Chan, D.S.; Wang, H.M.; Chan, P.W.; Ma, D.L.; Leung, C.H. Structure-based repurposing of FDA-approved drugs as inhibitors of NEDD8-activating enzyme. Biochimie, 2014, 102, 211-215. [http://dx.doi.org/10.1016/j.biochi.2014.03.005]. [PMID: 24657219].
[85]
Wu, K.J.; Zhong, H.J.; Li, G.; Liu, C.; Wang, H.D.; Ma, D.L.; Leung, C.H. Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing. Eur. J. Med. Chem., 2018, 143, 1021-1027. [http://dx.doi.org/10.1016/j.ejmech.2017.11.101]. [PMID: 29232579].
[86]
Scott, D.C.; Sviderskiy, V.O.; Monda, J.K.; Lydeard, J.R.; Cho, S.E.; Harper, J.W.; Schulman, B.A. Structure of a RING E3 trapped in action reveals ligation mechanism for the ubiquitin-like protein NEDD8. Cell, 2014, 157(7), 1671-1684. [http://dx.doi.org/10.1016/j.cell.2014.04.037]. [PMID: 24949976].
[87]
Scott, D.C.; Hammill, J.T.; Min, J.; Rhee, D.Y.; Connelly, M.; Sviderskiy, V.O.; Bhasin, D.; Chen, Y.; Ong, S.S.; Chai, S.C.; Goktug, A.N.; Huang, G.; Monda, J.K.; Low, J.; Kim, H.S.; Paulo, J.A.; Cannon, J.R.; Shelat, A.A.; Chen, T.; Kelsall, I.R.; Alpi, A.F.; Pagala, V.; Wang, X.; Peng, J.; Singh, B.; Harper, J.W.; Schulman, B.A.; Guy, R.K. Blocking an N-terminal acetylation-dependent protein interaction inhibits an E3 ligase. Nat. Chem. Biol., 2017, 13(8), 850-857. [http://dx.doi.org/10.1038/nchembio.2386]. [PMID: 28581483].
[88]
Hammill, J.T.; Scott, D.C.; Min, J.; Connelly, M.C.; Holbrook, G.; Zhu, F.; Matheny, A.; Yang, L.; Singh, B.; Schulman, B.A.; Guy, R.K. Piperidinyl ureas chemically control defective in cullin neddylation 1 (dcn1)-mediated cullin neddylation. J. Med. Chem., 2018, 61(7), 2680-2693. [http://dx.doi.org/10.1021/acs.jmedchem.7b01277]. [PMID: 29547696].
[89]
Hammill, J.T.; Bhasin, D.; Scott, D.C.; Min, J.; Chen, Y.; Lu, Y.; Yang, L.; Kim, H.S.; Connelly, M.C.; Hammill, C.; Holbrook, G.; Jeffries, C.; Singh, B.; Schulman, B.A.; Guy, R.K. Discovery of an orally bioavailable inhibitor of defective in cullin neddylation 1 (dcn1)-mediated cullin neddylation. J. Med. Chem., 2018, 61(7), 2694-2706. [http://dx.doi.org/10.1021/acs.jmedchem.7b01282]. [PMID: 29547693].
[90]
Zhou, H.; Lu, J.; Liu, L.; Bernard, D.; Yang, C.Y.; Fernandez-Salas, E.; Chinnaswamy, K.; Layton, S.; Stuckey, J.; Yu, Q.; Zhou, W.; Pan, Z.; Sun, Y.; Wang, S. A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation. Nat. Commun., 2017, 8(1), 1150. [http://dx.doi.org/10.1038/s41467-017-01243-7]. [PMID: 29074978].
[91]
Zhou, H.; Zhou, W.; Zhou, B.; Liu, L.; Chern, T.R.; Chinnaswamy, K.; Lu, J.; Bernard, D.; Yang, C.Y.; Li, S.; Wang, M.; Stuckey, J.; Sun, Y.; Wang, S. High-affinity peptidomimetic inhibitors of the dcn1-ubc12 protein-protein interaction. J. Med. Chem., 2018, 61(5), 1934-1950. [http://dx.doi.org/10.1021/acs.jmedchem.7b01455]. [PMID: 29438612].
[92]
Richardson, K.S.; Zundel, W. The emerging role of the COP9 signalosome in cancer. Mol. Cancer Res., 2005, 3(12), 645-653. [http://dx.doi.org/10.1158/1541-7786.MCR-05-0233]. [PMID: 16380502].
[93]
Schlierf, A.; Altmann, E.; Quancard, J.; Jefferson, A.B.; Assenberg, R.; Renatus, M.; Jones, M.; Hassiepen, U.; Schaefer, M.; Kiffe, M.; Weiss, A.; Wiesmann, C.; Sedrani, R.; Eder, J.; Martoglio, B. Targeted inhibition of the COP9 signalosome for treatment of cancer. Nat. Commun., 2016, 7, 13166. [http://dx.doi.org/10.1038/ncomms13166]. [PMID: 27774986].